Clinical Trials Logo

Metastases, Neoplasm clinical trials

View clinical trials related to Metastases, Neoplasm.

Filter by:

NCT ID: NCT05419518 Recruiting - Clinical trials for Metastases, Neoplasm

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Start date: March 16, 2023
Phase: Phase 2
Study type: Interventional

The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases

NCT ID: NCT03670992 Completed - Clinical trials for Renal Cell Carcinoma

Surgical Treatment of Pancreatic RCC Metastases

Start date: January 10, 2016
Phase:
Study type: Observational

Data from 26 patients undergoing resection of Pancreatic Metastases and extra-Pancreatic Metastases from RCC were retrospectively analysed. Clinical data were collected from a digital database and QoL was assessed through patient's interview and Karnofsky performance scale.

NCT ID: NCT03563326 Recruiting - Clinical trials for Metastases, Neoplasm

Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)

Start date: August 30, 2018
Phase: Phase 1
Study type: Interventional

To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.

NCT ID: NCT02265549 Completed - Clinical trials for Metastases, Neoplasm

Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

Start date: May 2014
Phase: N/A
Study type: Observational

Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.

NCT ID: NCT01115803 Terminated - Clinical trials for Renal Cell Carcinoma

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Start date: March 2010
Phase: Phase 1
Study type: Interventional

Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.

NCT ID: NCT01115751 Completed - Clinical trials for Metastases, Neoplasm

A Study in Patients With Advanced or Metastatic Cancer

Start date: March 2010
Phase: Phase 1
Study type: Interventional

Study JWAA is a multicenter, nonrandomized, open-label, dose-escalation Phase 1 study of oral LY2780301 in patients with advanced solid tumors.

NCT ID: NCT00065117 Terminated - Clinical trials for Colorectal Neoplasms

Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.

Start date: September 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.

NCT ID: NCT00056173 Completed - Clinical trials for Carcinoma, Renal Cell

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Start date: March 2002
Phase: Phase 1/Phase 2
Study type: Interventional

This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

NCT ID: NCT00055471 Completed - Prostatic Neoplasms Clinical Trials

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

Start date: June 2003
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

NCT ID: NCT00054795 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Start date: n/a
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.